POTI', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 2.864
AS - Asia 2.317
EU - Europa 1.850
SA - Sud America 391
AF - Africa 131
Continente sconosciuto - Info sul continente non disponibili 7
Totale 7.560
Nazione #
US - Stati Uniti d'America 2.805
SG - Singapore 999
CN - Cina 724
IT - Italia 430
BR - Brasile 319
IE - Irlanda 316
SE - Svezia 245
HK - Hong Kong 222
FI - Finlandia 209
DE - Germania 179
VN - Vietnam 150
UA - Ucraina 123
ZA - Sudafrica 99
NL - Olanda 93
TR - Turchia 79
RU - Federazione Russa 68
AT - Austria 43
GB - Regno Unito 43
CA - Canada 39
AR - Argentina 36
FR - Francia 29
IN - India 27
ID - Indonesia 17
BE - Belgio 15
MX - Messico 15
IQ - Iraq 14
BD - Bangladesh 13
CZ - Repubblica Ceca 13
JP - Giappone 13
KR - Corea 12
PL - Polonia 12
CI - Costa d'Avorio 9
EC - Ecuador 9
CL - Cile 7
EU - Europa 7
PK - Pakistan 6
CO - Colombia 5
ES - Italia 5
IR - Iran 5
JO - Giordania 5
PY - Paraguay 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
EG - Egitto 4
LT - Lituania 4
RO - Romania 4
GR - Grecia 3
KZ - Kazakistan 3
MA - Marocco 3
MY - Malesia 3
NP - Nepal 3
TN - Tunisia 3
VE - Venezuela 3
AL - Albania 2
BO - Bolivia 2
BY - Bielorussia 2
DZ - Algeria 2
ET - Etiopia 2
KE - Kenya 2
PE - Perù 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
GF - Guiana Francese 1
GH - Ghana 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
NA - Namibia 1
NG - Nigeria 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
TL - Timor Orientale 1
Totale 7.560
Città #
Singapore 502
Chandler 349
Dublin 316
Ashburn 305
Santa Clara 269
Hong Kong 219
Beijing 202
Dallas 201
Ann Arbor 145
Jacksonville 140
Parma 109
Dearborn 108
Boardman 100
Johannesburg 87
Houston 86
New York 86
Princeton 73
Izmir 68
Nanjing 65
Ho Chi Minh City 52
Wilmington 52
Hefei 47
Chicago 43
Hanoi 40
Shanghai 39
Los Angeles 37
Vienna 36
Columbus 35
Helsinki 32
Moscow 32
San Mateo 31
Munich 30
São Paulo 29
Bremen 27
Toronto 27
Nanchang 24
Des Moines 23
Milan 23
Seattle 22
Hebei 20
Jinan 20
Rho 20
Shenyang 20
The Dalles 18
Buffalo 17
Bologna 15
Brussels 15
Jiaxing 15
Changsha 14
Fremont 14
Guangzhou 14
Jakarta 14
Tianjin 14
Tokyo 13
Belo Horizonte 12
Brooklyn 12
Haiphong 12
Seoul 12
Kunming 11
Modena 11
Brno 10
Council Bluffs 10
Fairfield 10
Turku 10
Abidjan 9
Denver 9
Rio de Janeiro 9
Zhengzhou 9
Stockholm 8
Warsaw 8
Washington 8
Chengdu 7
Frankfurt am Main 7
Grafing 7
Hangzhou 7
Nuremberg 7
Redondo Beach 7
San Francisco 7
London 6
Rockville 6
Amman 5
Baghdad 5
Bergamo 5
Brasília 5
Düsseldorf 5
Faenza 5
Manchester 5
Marseille 5
Ottawa 5
Phoenix 5
Pune 5
Reggio Emilia 5
Taiyuan 5
Woodbridge 5
Amsterdam 4
Atlanta 4
Betim 4
Biên Hòa 4
Borås 4
Boston 4
Totale 4.679
Nome #
Treatments for COVID-19: emerging drugs against the coronavirus 219
Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells in vitro 201
PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice 186
Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability 182
Effects of the radiocontrast agent iodixanol on endothelial cell morphology and function. 158
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 157
A Short Term Administration of Cyclosporine A to Mice Inhibits the Reverse Cholesterol Transport from Macrophages 149
CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO BY REDUCING STEROL FECAL EXCRETION 145
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) GENETIC DELETION ATTENUATES AMYLOID-. PATHOLOGY, NEUROINFLAMMATION AND IMPROVES COGNITIVE FUNCTIONS IN AN ALZHEIMER'S DISEASE MOUSE MODEL 138
EFFETTI DEI MEZZI DI CONTRASTO E DELLA N-ACETILCISTEINA SU MORFOLOGIA E FUNZIONE DELLE CELLULE ENDOTELIALI UMANE 129
Critical and emerging topics in dietary carbohydrates and health 128
Alcohol pattern consumption differently affects the efficiency of macrophage reverse cholesterol transport in vivo 126
LA CICLOSPORINA A INIBISCE IL TRASPORTO INVERSO DEL COLESTEROLO NEI TOPI 125
Drug-drug interactions in polypharmacy patients: The impact of renal impairment 125
Macrophage, But Not Systemic, Apolipoprotein E Is Necessary for Macrophage Reverse Cholesterol Transport In Vivo 124
HDL and reverse cholesterol transport in humans and animals: Lessons from pre-clinical models and clinical studies 124
Cyclosporine A modulates the macrophage reverse cholesterol transport in vivo 123
Polyphenol health effects on cardiovascular and neurodegenerative disorders: A review and meta-analysis 122
CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO BY REDUCING STEROL FECAL EXCRETION 120
EFFECTS OF RADIOLOGY CONTRAST MEDIA ON CULTURED HUMAN ENDOTHELIAL CELL MORPHOLOGY AND FUNCTION AND PROTECTIVE ACTION OF N-ACETYLCYSTEIN AND ROSUVASTATIN 118
'Spare' Luteinizing Hormone Receptors: Facts and Fiction 117
Effetto della Ciclosporina A sul trasporto inverso del colesterolo in vivo 116
LA CICLOSPORINA A RIDUCE IL TRASPORTO INVERSO DEL COLESTEROLO NEI TOPI ATTRAVERSO L’INIBIZIONE DELL’ESCREZIONE FECALE 116
Effetto degli agonisti LXR sul trasporto inverso del colesterolo in vivo 114
RUOLO DELLA SFINGOSINA 1-FOSFATO E DEL SUO RECETTORE S1P3 NEL TRASPORTO INVERSO DEL COLESTEROLO 113
A SHORT TERM ADMINISTRATION OF CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO 112
Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion 112
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 106
Biglycan and atherosclerosis: Lessons from high cardiovascular risk conditions 103
The LXR agonist T0901317 promotes the reverse cholesterol transport frommacrophages by increasing plasma efflux potential 101
IN VIVO TREATMENT WITH CYCLOSPORINE A INCREASES EFFLUX POTENTIAL OF MOUSE PLASMA VIA ATP-BINDING CASSETTE TRANSPORTER ABCA1 97
Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo 97
Aortic Gene Expression Profiles Show How ApoA-I Levels Modulate Inflammation, Lysosomal Activity, and Sphingolipid Metabolism in Murine Atherosclerosis 97
Dual effect of statins on ABCA1-mediated lipid efflux from macrophages and hepatic cells 96
TRASPORTO INVERSO DEL COLESTEROLO: FATTORI DETERMINANTI L’EFFICIENZA DEL PROCESSO 95
ROLE OF APOLIPOPROTEIN E IN THE REVERSE CHOLESTEROL TRANSPORT IN VIVO 95
Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) 93
Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis 92
Impact of dietary lipids on the reverse cholesterol transport: What we learned from animal studies 92
Impact of apolipoprotein E (apoE) deficiency on reverse cholesterol transport in vivo 91
Effect of LXR agonists on reverse cholesterol transport in vivo 90
Sphingosine-1 phosphate induces cAMP/PKA-independent phosphorylation of the cAMP response element-binding protein (CREB) in granulosa cells 88
Meccanismo di attivazione dell’ATP-binding cassette A1 da parte del cAMP 82
Pharmacogenetics of GPCR variants: FSH receptor and infertility treatment 82
The liver-X-receptor agonist T0901317 stimulates in vivo reverse cholesterol transport in mice 81
Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R-/-) Mice 81
The in vivo stimulation of LXR promotes the reverse cholesterol transport in vivo by increasing the efflux potential of sera 77
Effect of the LXR agonist T0901317 on reverse cholesterol transport in vivo 77
EFFECTS OF RADIOLOGY CONTRAST MEDIA ON CULTURED HUMAN ENDOTHELIAL CELL MORPHOLOGY AND FUNCTION AND PROTECTIVE ACTION OF N-ACETYLCYSTEIN AND ROSUVASTATIN 77
Apolipoprotein M and Sphingosine-1-Phosphate Receptor 1 Promote the Transendothelial Transport of High-Density Lipoprotein 76
Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis 75
La rosuvastatina promuove il trasporto inverso del colesterolo nei topi 74
Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice 74
COVID-19 … What are drugs and strategies now? 72
In vivo stimulation of LXR increases the efflux potential of sera and promotes the reverse cholesterol transport 72
Il cAMP attiva l’ATP-Binding Cassette A1 (ABCA1) attraverso un duplice meccanismo 71
SKI-II - a sphingosine kinase 1 inhibitor - exacerbates atherosclerosisin low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet 71
The LXR agonist T0901317 increases the efflux potential of sera and promotes the reverse cholesterol transport in mice 69
Inferring biallelism of two FSH receptor mutations associated with spontaneous ovarian hyperstimulation syndrome by evaluating FSH, LH and HCG cross-activity 69
Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP 69
Sphingolipids and atherosclerosis: focus on Sphingosine 1-Phosphate (S1P) 67
Identification of sclerostin as a putative new myokine involved in the muscle-to-bone crosstalk 64
Sphingosine 1-Phosphate (S1P): a bridge between HDL, inflammation and atherosclerosis? 63
KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/-mice 63
Gnrh antagonists produce differential modulation of the signaling pathways mediated by gnrh receptors 62
Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of high-density lipoproteins and low-density lipoproteins in opposite ways 61
Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro 61
Glycosylation pattern and in vitro bioactivity of reference follitropin alfa and biosimilars 60
LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro 58
Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R-/-) mice 58
Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R -/-) mice 57
Seizures of illicit substances for personal use in two Italian provinces: Analysis of trends by type and purity from 2008 to 2017 57
Editorial: Pharmacology of endocrine related GPCRs 56
High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression 56
WISP-2 expression induced by Teriparatide treatment affects in vitro osteoblast differentiation and improves in vivo osteogenesis 54
Treatments for COVID-19: Emerging drugs against the coronavirus-reply 53
Osteocytes specific GSK3 inhibition affects in vitro osteogenic differentiation 51
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 48
Molecular basis of androgen action on human sexual desire 46
The “hitchhiker’s guide to the galaxy” of endothelial dysfunction markers in human fertility 44
Sphingosine 1-phosphate receptor 1 signaling in macrophages reduces atherosclerosis in LDL receptor–deficient mice 43
Totale 7.663
Categoria #
all - tutte 29.379
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.379


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021309 0 0 0 0 0 57 39 14 73 12 85 29
2021/2022399 21 15 16 9 25 18 65 54 20 27 6 123
2022/20231.260 140 100 79 114 131 147 13 89 380 14 41 12
2023/2024557 23 42 13 21 26 140 31 54 19 34 45 109
2024/20251.732 46 88 115 126 185 210 49 63 231 152 134 333
2025/20262.097 356 396 443 273 578 51 0 0 0 0 0 0
Totale 7.663